PLAUR and type 2 diabetes mellitus: Recently, a proof‐of‐concept study revealed that FMD can also improve HOMA‐IR and soluble urokinase plasminogen activator receptor in patients with T2DM and diabetic nephropathy, effectively inhibiting the development of T2DM and its complications.142